Pharmacologic inhibition of lipoprotein-associated phospholipase A2 (Lp-PLA2) does not reduce cardiovascular event rates, and therefore Lp-PLA2 is not a goal of therapy, nor is it an FDA-approved or health insurance-reimbursed test.

Authors

• Person: Not available Organization: National Lipid Association
  EBM Tools for Practice: Best Biomarkers for Inflammation

Sources

• EBM Tools for Practice: Best Biomarkers for Inflammation www.lipid.org National Lipid Association via serper

Referenced by nodes (2)

• cardiovascular events concept
• health insurance concept